Modality
Gene Editing
MOA
KRASG12Di
Target
CD20
Pathway
RNA Splicing
Urothelial CaHeart FailureGBM
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Sep 2029
ApprovedCurrent
NCT03146815
1,232 pts·Urothelial Ca
2025-07→2029-09·Completed
NCT04789551
1,767 pts·GBM
2019-10→TBD·Completed
NCT06876875
800 pts·GBM
2017-10→2029-09·Recruiting
3,799 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2029-09-023.4y awayPh3 Readout· GBM
2029-09-093.4y awayPh3 Readout· Urothelial Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Recruit…
Approved
Complet…
Approved
Complet…
Catalysts
Ph3 Readout
2029-09-02 · 3.4y away
GBM
Ph3 Readout
2029-09-09 · 3.4y away
Urothelial Ca
RecruitingCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03146815 | Approved | Urothelial Ca | Completed | 1232 | PASI75 |
| NCT04789551 | Approved | GBM | Completed | 1767 | UPDRS |
| NCT06876875 | Approved | GBM | Recruiting | 800 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 |